ema prac naion semaglutide very rare side effect 2025 Eye disorder is a 'very rare' of weight-loss drugs, concludes review Novo Nordisk refutes link between

As a result, the committee asked drug manufacturer Novo Nordisk to list the eye condition as a very rare side effect in their semaglutide medications

While its primary FDA indication is glucose regulation, Ozempic shares the same GLP-1 mechanism as Wegovy and often produces significant appetite reduction and weight loss in patients who receive it for diabetes or metabolic dysfunction

The medication helps regulate appetite, but patients should still continue to follow healthy eating patterns and engage in physical activity

The simplicity of phentermine dosing is convenient but reflects the drug limitations rather than precision dosing strategies

Remember, patience and consistency are vital to your success